FindTrial
Sign In

Fluorouracile

DRUG3 trials

Sponsors

Centre Jean Perrin, Gustave Roussy, Cancer Campus, Grand Paris, UNICANCER

Conditions

Neoadjuvant Operable Breast CancerPathological Response RatePatients With Colorectal Cancer With Unresectable Synchronous Metastasis in Whom Resection of the Primitive Tumour is Indicated

Phase 2

Assessment of the Efficacy of the Neoadjuvant Combination: Chemotherapy-Targeted Therapy in Breast Cancer.
CompletedNCT00933517
Centre Jean PerrinPathological Response Rate
Start: 2009-09-30End: 2011-10-31Updated: 2014-03-21
Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer
TerminatedNCT01715363
Gustave Roussy, Cancer Campus, Grand ParisPatients With Colorectal Cancer With Unresectable Synchronous Metastasis in Whom Resection of the Primitive Tumour is Indicated
Start: 2012-07-31End: 2014-06-30Updated: 2016-02-10
Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women
CompletedNCT02400567
UNICANCERNeoadjuvant Operable Breast Cancer
Start: 2015-01-31End: 2020-09-30Updated: 2022-03-15

Related Papers

4MO Neoadjuvant letrozole and palbociclib versus chemotherapy in the NeoPAL study: A translational analysis
ESMO Open2024-05-01
131P Efficacy of neoadjuvant letrozole and palbociclib in HER2-low vs HER2 zero luminal breast cancer: An analysis of the Unicancer Neopal phase II study
ESMO Open2023-05-01
Abstract PS12-03: Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study
Cancer Research2021-02-15
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials.
2020-01-3115 citations
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
2018-12-01126 citations
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
2014-05-1492 citations